Atrial Fibrillation
Conditions
Keywords
Left Atrial Appendage Occlusion, Stroke Risk
Brief summary
Randomized controlled trial assessing the safety and efficacy of the LAmbre Plus LAA Closure System to rescue the risk of thromboembolism in patients with non-valvular AF.
Detailed description
The goal of this clinical trial is to demonstrate the safety and efficacy of the LAmbre Plus device in patients with non-valvular atrial fibrillation in comparison with the commercially available transcatheter LAAO device(s). The main questions it aims to answer are: Overall safety of the device that is assessed at the 12 month time period. Overall efficacy, after all subjects have reached the 18 month time period. Participants will be randomized to either the LAmbre device or other FDA approved LAAO devices.
Interventions
DEVICELAmbre investigational device
Randomized 1:1 to either experimental group or control group.
Sponsors
Kansas City Heart Rhythm Research Foundation
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Masking description
Patients and family will be blinded to which device they received.
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* The patient is a male or non-pregnant female ≥18 years of age * The patient has documented paroxysmal, persistent, or permanent non- valvular atrial fibrillation * The patient has a CHADS2 score ≥ 2 or a CHA2DS2-VASc score of ≥ 3, and is recommended for oral anticoagulation therapy * The patient is deemed by their physician to be suitable for short-term warfarin therapy, but there is an appropriate rationale for seeking a non-pharmacologic alternative to oral anticoagulation * The patient is deemed suitable for LAA closure by a multidisciplinary heart team, including at least 1 investigator (e.g. cardiologists) and 1 clinician not involved as part of the procedure team using a shared decision making process, and this determination has been documented in the patient's medical record * The patient is willing and able to comply with protocol-specified treatment and follow-up evaluations * The patient (or his or her legally authorized representative) has been informed of the nature of the study, agrees to its provisions, and has been provided written informed consent approved by the appropriate Institutional Review Board (IRB) or Ethics Committee (EC)
Exclusion criteria
* Pregnant or nursing patients and those who plan pregnancy in the period up to 1 year following index procedure. Female patients of childbearing potential must have a negative pregnancy test done within 7 days prior to index procedure per site standard test. * Patients with atrial fibrillation that is defined by a single occurrence, or that is transient or reversible (e.g., secondary to CABG, an interventional procedure, pneumonia, or hyperthyroidism) * Patients who require long-term anticoagulation for a condition other than atrial fibrillation * Patients with an indication for chronic P2Y12 platelet inhibition therapy * Patients not suitable for short term warfarin (including due to bleeding diathesis or coagulopathy or absolute contraindication warfarin) or who will refuse transfusion * Patients with rheumatic mitral valve disease, known severe aortic stenosis requiring surgical or percutaneous valve replacement, or existing mechanical valve prosthesis * Active infection with bacteremia * Known hypersensitivity or contraindication to aspirin, clopidogrel, heparin/bivalirudin, any device material or component (nitinol, nickel, titanium, PET), and/or contrast sensitivity that cannot be adequately pre-medicated * Anatomic conditions that would prevent performance of the LAA occlusion procedure (e.g., prior atrial septal defect \[ASD\] or patient foramen ovale \[PFO\] surgical repair or implanted closure device, or obliterated left atrial appendage) * Recent (within 30 days pre-procedure) or planned (within 60 days post- procedure) cardiac or non-cardiac interventional or surgical procedure (e.g., cardioversion, ablation, percutaneous coronary intervention, cataract surgery, etc.) * Recent (within 90 days pre-procedure) stroke, transient ischemic attack, or myocardial infarction * Severe heart failure (New York Heart Association Class IV) * Known asymptomatic carotid artery disease with\>70% diameter stenosis OR symptomatic carotid disease (\>50% diameter stenosis with ipsilateral stroke or TIA). Subjects with prior carotid endarterectomy or carotid stent placement may be enrolled, provided that known diameter stenosis is \<50%. * Past or pending heart or any other organ transplant, or on the waiting list for any organ transplant * Known other medical illness or known history of substance abuse that may cause non-compliance with the protocol, confound data interpretation, or is associated with a life expectancy of less than 2 years * Current participation in another investigational drug or device study Echocardiographic
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Major adverse event - major bleeding | up to 7 days following implant procedure | Visual bleeding or a drop in hemoglobin of 2 units and requiring transfusion. |
| Major procedure related complications - cardiac perforation | up to 7 days following implant procedure | Cardiac perforation can be seen interprocedurally through ICE or TEE, post procedurally via TTE or TEE. |
| Major procedure related complications - pericardial effusion with tamponade or requiring drainage | up to 7 days following implant procedure | Common complications can be seen interprocedurally through ICE or TEE, post procedurally via TTE or TEE. |
| Major procedure related complications - device embolization | up to 7 days following implant procedure | Procedure complications can be seen interprocedurally through ICE or TEE, post procedurally via TTE or TEE. |
| Major adverse event - Death | up to 7 days following implant procedure | Death is observed by lack of oxygen, lack of pulse, succession of neurological activity. |
| Major adverse event - all strokes | up to 7 days following implant procedure | Stroke is identified by neurologic imaging and transient or permanent motor or sensory deficient. |
| Major adverse event - systemic embolization | up to 7 days following implant procedure | Systemic embolization assessed by onsite symptoms and confirmed by diagnostic imaging. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Major adverse event | 45 days, 6 months, 12 months, 18 months and 2, 3, 4, and 5 years | composite of cardiovascular death, overs CNS injury and major bleeding |
| mortality | 45 days, 6 months, 12 months, 18 months and 2, 3, 4, and 5 years | cardiovascular or non-cardiovascular and reported cumulatively and individually |
| myocardial infarction | 45 days, 6 months, 12 months, 18 months and 2, 3, 4, and 5 years | Defined as ST or nonST ECG changes with positive cardiac bio markers. |
| periprocedural stroke | 45 days, 6 months, 12 months, 18 months and 2, 3, 4, and 5 years | Motor and sensory deficits observed and imaging confirmed. |
| bleeding complications | 45 days, 6 months, 12 months, 18 months and 2, 3, 4, and 5 years | Visual bleeding or a drop in hemoglobin |
| major procedure-related complications | 45 days, 6 months, 12 months, 18 months and 2, 3, 4, and 5 years | vascular or cardiac complications occurring due to the procedure. |
| vascular complications | 45 days, 6 months, 12 months, 18 months and 2, 3, 4, and 5 years | vascular complications are hematomas, aneurysms, and ischemic limb. |
Contacts
Primary ContactDonita Atkins, RN, BSN
Outcome results
None listed